Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth
The suspense over who will succeed John Milligan at Gilead has finally ended.
Daniel O’Day, current CEO of Roche’s Pharma division, has been tapped for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
